Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics

Bone Marrow Transplantation

Volumn 24, Issue 1, 1999, Pages 1-4

  Cagnoni, P J ^a,b   Matthes, S ^a   Day, T C ^a   Bearman, S I ^a   Shpall, E J ^a   Jones, R B ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Chemotherapy; Ondansetron; Prochlorperazine

Indexed keywords

ANTIEMETIC AGENT; CARMUSTINE; CISPLATIN; DIPHENHYDRAMINE; LORAZEPAM; ONDANSETRON; PROCHLORPERAZINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; MALE; PHARMACOKINETICS; PRIORITY JOURNAL;

EID: 0032801763     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701832     Document Type: Article

References (19)

1. Armitage JO. Bone marrow transplantation. New Engl J Med 1994; 330: 827-838.
2. Petersen FB, Bearman SI. Preparative regimens and their toxicity. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation, edn 1. Blackwell: Boston, MA, 1994, pp 79-95.
3. Jones RB, Matthes S, Shpall EJ et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin ,and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst 1993; 85: 640-647.
4. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
5. Ayash LJ, Wright JE, Tretyakov O et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992; 10: 995-1000.
6. Stemmer SM, Cagnoni PJ, Shpall EJ et al. High-dose paclitaxel, cyclophosphamide and cisplatin with autologous hematopoietic progenitor cell support: a phase I trial. J Clin Oncol 1996; 14: 1463-1472.
7. Gilbert CJ, Petros WP, Cavanaugh C et al. Influence of ondansetron on the pharmacokinetics of high-dose cyclophosphamide. Proc Am Soc Clin Oncol 1995; 14: 316a.
8. Gilbert CJ, Ohly KV, Rosner G, Peters WP. Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. Cancer 1995; 76: 2330-2337.
9. Perez EA. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 1995; 13: 1036-1043.
10. Cagnoni PJ, Matthes S, Dufton C et al. Ondansetron significantly reduces the area under the curve of cyclophosphamide and cisplatin. Proc Am Soc Clin Oncol 1995; 14: 462a.
11. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant chemotherapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
12. Shpall EJ, Jones RB, Franklin W et al. Transplantation of enriched CD-34 positive (+) autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD-34+ peripheral blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
13. El-Yazigi A, Martin C. Improved analysis of cyclophosphamide by capillary gas chromatography with termionic (nitrogenphosphorus) detection and silica sample purification. J Chromatogr 1986; 374: 177-182.
14. Hsyu PH, Pritchard JF, Bozigian HP et al. Oral ondansetron pharmacokinetics: the effect of chemotherapy. J Clin Pharmacol 1994; 34: 767-773.
15. 3-receptor antagonist. Am J Med Sci 1992; 304: 373-378.
16. Jones RB, Matthes S. Pharmacokinetics. In: Armitage JO, Antman KH (eds). High-Dose Cancer Therapy: Pharmacology, Hemopoietins Stem Cells. Williams and Wilkins: Baltimore, 1992, pp 43-60.
17. Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53: 5629-5637.
18. Guengerich FP. Human cytochrome P450 enzymes. In: Paul R, Montellan O (eds). Cytochrome P450: Structure, Mechanism, and Biochemistry, 2nd edn. Plenum Press: New York, 1995, pp 473-535.
19. LeBlanc GA, Sundseth SS, Weber GF, Waxman DJ. Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res 1992; 52: 540-547.